<DOC>
	<DOCNO>NCT00599924</DOCNO>
	<brief_summary>This study determine maximum tolerate dose safety SU011248 ( sunitinib malate , SUTENT ) combination FOLFOX [ Leucovorin + Fluorouracil ( 5-FU ) + Oxaliplatin ] . Three different dose regimen start dos sunitinib 37.5 mg/day ( Schedule 2/2 , Schedule 4/2 , Continuous Dosing ) test patient advance solid tumor , include colorectal cancer .</brief_summary>
	<brief_title>Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors</brief_title>
	<detailed_description>Study Design : Treatment , Single Group Assignment ( 7 cohort ) , Open Label , Non-Randomized , Safety Study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Advanced solid tumor malignancy ( expansion maximum tolerate dose , entry limit patient wtih adenocarcinoma colon rectum ) Eastern Cooperative Oncology Group ( ECOG ) 0 1 Prior treatment 6 cycle traditional alkylating agentbased chemotherapy regimens Prior treatment 2 cycle carboplatingbased chemotherapy regimen For colorectal cancer patient expand cohort , prior treatment 2 systemic chemotherapy regimen metastatic setting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>advanced solid tumor ,</keyword>
	<keyword>colorectal cancer ,</keyword>
	<keyword>sunitinib ( SUTENT ) ,</keyword>
	<keyword>FOLFOX</keyword>
</DOC>